In this commentary, Jay Wish, MD, shares his insights on the burden of anemia with CKD and the barriers to appropriate management.
Here’s my take on why and how we can do better when treating our patients with anemia of chronic kidney disease.
Here’s my take on a promising new class of agents in development to treat anemia of CKD, their distinct advantages and disadvantages, and their potential place in therapy, if approved.
Here’s my take on how we can begin to tackle health disparities in patients with anemia of CKD.
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.